-The Times of India NEW DELHI: The Supreme Court on Monday gave a last opportunity to the Centre to break its long silence over Election Commission's suggestion to ban those facing trial for heinous offences from contesting elections. Almost eight months after it directed the Centre and the EC to "positively" file its response to a PIL seeking a series of directions to ensure that those with criminal track records do not...

-The Times of India NEW DELHI: The Supreme Court on Wednesday said intercepted phone conversations of former corporate lobbyist Niira Radia indicated her alleged influence in every field of decision-making and wondered why investigating agencies, despite being aware of the Radia tape contents, did not take action for four years. "We are unable to appreciate one thing. Virtually in every field, which should be with the government, a private person, call her...

-Newsclick.in A few weeks back Fortune magazine and CNN carried a long online blog titled ‘Dirty Medicine' by Dinesh Thakur, a former employ of Ranbaxy, where he recounts how he came across several procedural and other lapses in the company's manufacturing facilities. Since then the Fortune blog has become one of the most widely circulated and commented upon business stories in the world. The story received attention as it came in the...

-The Telegraph Imphal: A Manipuri widow's cry for justice rang out during the 23rd session of the UN Human Rights Council this morning, as she questioned gaps in UN Special Rapporteur on extrajudicial, summary or arbitrary executions Christof Heyns's report on the Armed Forces (Special Powers) Act. Neena Ningobam, who represented the Extrajudicial Execution Victim Families' Association, Manipur, of which she is the secretary, and the Asian Legal Resource Centre (ALRC) at...

-The Hindu   Ranbaxy's fraudulent practices may have jeopardised millions of lives in India, Africa and the U.S. Exactly two weeks ago, the pharmaceuticals industry was rocked by revelations that one of the world's largest generic drug manufacturers, Ranbaxy Laboratories, pleaded guilty to seven federal criminal charges stemming from its fraudulent production practices dating back to 2008, and agreed to pay U.S. regulators $500 million in fines. Much has since been said about Ranbaxy's...